9924 Mesa Rim Road
22 articles with Allele Biotechnology
Allele Biotechnology and Pharmaceuticals Files Two Lawsuits for Patent Infringement for the Unauthorized Use of mNeonGreen in Development and Testing of COVID Vaccines and Therapeutics
New York Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. California Lawsuit Filed Against Pfizer, Inc. and BioNTech SE and BioNTech U.S., Inc. SAN DIEGO--( BUSINESS WIRE )-- Allele Biotechnology and Pharmaceuticals, Inc. (“Allele”), a San Diego-based company focused on developing and adapting cutting edge technology for clinical and therapeutic use, filed two patent infringement lawsuits today – one in New York against Regenero
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
Allele Biotechnology and Pharmaceuticals, Inc. has been using mRNA as its core technology for creating cGMP-grade iPSC lines for regenerative medicine and oncology for over a decade.
In their latest paper published in the online prepublication by the peer-reviewed journal Current Protocols, scientists and cGMP operation managers at Allele Biotechnology present a series of step-by-step protocols for manufacturers of iPSC and other types of stem cells with streamlined cleanroom practices for growing clinical grade cell products.
Allele and Addgene Partner to Increase Academic Access to the World’s Brightest Monomeric Fluorescent Protein
Allele Biotechnology and Pharmaceuticals Inc., a San Diego based biotechnology company focused on the development and clinical translation of cutting-edge technologies, has partnered with Addgene, a global nonprofit organization helping scientists share plasmids, to further facilitate academic use of mNeonGreen.
Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment
San Diego-based Allele Biotechnology and Pharmaceuticals, Inc., officially announced a joint research and development agreement with South Korea’s SCM Lifescience Co., Ltd., for the development of diabetes therapies using pancreatic beta cells derived from induced pluripotent stem cells.
Allele uses experts from Scientist.com’s Genius Consulting NetworkTM and proprietary internal technology to create innovative biologics programs
Allele Receives iPSC Patents Bolstering Current Production of Multiple Lines at Wholly Owned cGMP Facility
Allele Biotechnology & Pharmaceuticals Inc. has received issuance notices from the U.S. Patent and Trademark Office for its first batch of patents covering the derivation of induced pluripotent stem cells (iPSCs).
The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody (nAb) therapies for the treatment of sepsis.
10/15/2018The National Institute of General Medical Sciences, part of the National Institutes of Health, awarded Allele Biotechnology and Pharmaceuticals a Small Business Innovative Research grant to develop therapies for sepsis.
Allele is the world’s first establishment to collect tissue for the manufacture and banking of induced pluripotent stem cells (iPSCs) for commercial applications.
Allele Biotechnology To Develop iPSC-Derived Cell Therapies With Focus On Diabetes And Spinal Cord Injury
Ocata Therapeutics Licenses Induced Pluripotent Stem Cell Technology From Allele Biotechnology And Extends Leadership Position In Cell Therapy Capabilities
Allele Biotechnology Publishes mNeonGreen as the Brightest Monomeric Fluorescent Protein for Super-Resolution Imaging